Norway Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Norway recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Norway recombinant protein therapeutics cdmo market highlights
- The Norway recombinant protein therapeutics cdmo market generated a revenue of USD 265.0 million in 2023 and is expected to reach USD 647.9 million by 2030.
- The Norway market is expected to grow at a CAGR of 13.6% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 265.0 million |
| Market revenue in 2030 | USD 647.9 million |
| Growth rate | 13.6% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Norway accounted for 1.3% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 2,892.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.36% in 2023. Horizon Databook has segmented the Norway recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Ongoing advancements in biotechnology and protein engineering are enhancing the development and production of recombinant proteins. CDMOs play a crucial role in providing expertise and infrastructure for the efficient production of these complex molecules. Moreover, the pharmaceutical and biotechnology industries are investing heavily in R&D activities to discover and develop new recombinant protein therapeutics.
This increased R&D expenditure boosts the demand for CDMO services as companies seek external expertise to bring their products to market more efficiently. Norway allocates 8.1% of its Gross Domestic Product (GDP) to healthcare, positioning itself as one of the leading global spenders on healthcare.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Norway Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
